{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006393","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.775677+00:00","generated_at":"2026-05-22T13:25:33.756765+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences reports 20% Q1 revenue growth; reaffirms 2025 guidance $820-860M","bullets":["Q1 net revenue $184.7M, +20% YoY; GAAP net income $45.6M ($0.78 diluted EPS).","Non-GAAP adjusted net income $60.4M ($1.03 diluted EPS) vs $50.7M ($0.88) YoY.","Reaffirms FY2025 revenue guidance $820-$860M; cash and investments >$600M.","ZYN002 Phase 3 in Fragile X completed recruitment; topline data on track for Q3 2025.","Pitolisant HD Phase 3 registrational trials in narcolepsy & IH on track to initiate Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006393","json":"https://secwatch.observer/filing/0001558370-25-006393.json","markdown":"https://secwatch.observer/filing/0001558370-25-006393.md","text":"https://secwatch.observer/filing/0001558370-25-006393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/0001558370-25-006393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/hrmy-20250506x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T13:25:33.756765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}